Breast Cancer Gene (BRCA) Mutations Treatment Market Report 2026

The breast cancer gene (brca) mutations treatment market size has grown strongly in recent years. It will grow from $5.01 billion in 2025 to $5.37 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to limited awareness of brca mutations, restricted access to genetic testing services, reliance on conventional chemotherapy, increasing incidence of breast and ovarian cancer, gradual adoption of targeted therapies.

The breast cancer gene (brca) mutations treatment market size is expected to see strong growth in the next few years. It will grow to $7 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to advancements in genomic sequencing technologies, expansion of parp inhibitor indications, rising investment in precision oncology, increasing adoption of combination therapies, supportive reimbursement policies for genetic testing and targeted treatments. Major trends in the forecast period include rising adoption of genetic testing and early brca mutation screening, growing use of parp inhibitors in targeted therapy, increasing focus on preventive and risk-reduction treatment strategies, expansion of personalized and precision oncology approaches, improved access to multimodal treatment options for brca-related cancers.

The increasing demand for targeted therapies is expected to drive the growth of the breast cancer gene (BRCA) mutation treatment market in the coming years. Targeted therapies are medical treatments designed to specifically attack cancer cells by focusing on genetic mutations or proteins that contribute to cancer progression. The rising demand for targeted therapies is largely attributed to their ability to selectively target disease-causing cells or molecular pathways while minimizing damage to healthy tissues, leading to improved treatment efficacy and fewer side effects compared to conventional therapies. Targeted therapies support the treatment of breast cancer gene (BRCA) mutations by providing precision medicines that directly address the genetic alterations responsible for disease development, thereby improving clinical outcomes and reducing unnecessary adverse effects. For example, in July 2023, according to a report published by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, there were 247 gene therapies in Phase II at the end of Q1 2023, and this number increased by 5% to reach 260 by the end of Q2 2023. Therefore, the increasing demand for targeted therapies is driving the growth of the breast cancer gene (BRCA) mutation treatment market.

The growing focus on personalised medicine is also expected to propel the growth of the breast cancer gene (BRCA) mutation treatment market going forward. Personalised medicine involves tailoring medical treatments to an individual’s unique genetic, biological, and clinical profile. The rising emphasis on personalised medicine is driven by advancements in genetic testing technologies, which enable more precise treatment selection based on a patient’s biological makeup. This growing focus is transforming the management of BRCA gene mutations by enabling customized risk assessment, targeted therapies such as PARP inhibitors, and individualized preventive strategies that enhance treatment effectiveness while minimizing adverse effects, ultimately improving outcomes for patients with hereditary breast and ovarian cancers. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, compared to six approvals in 2022. These newly approved personalized treatments included seven cancer drugs and three therapies for other diseases and conditions. Therefore, the growing focus on personalised medicine is driving the growth of the breast cancer gene (BRCA) mutation treatment market.

In October 2024, Owkin Inc., a US-based biotechnology company, partnered with AstraZeneca plc to accelerate and expand access to germline BRCA (gBRCA) pre-screening. The partnership aims to develop an AI-driven gBRCA pre-screening tool that uses digitized pathology slides to accelerate and broaden access to breast cancer gene (BRCA) mutation testing among breast cancer patients. AstraZeneca plc is a UK-based biopharmaceutical company specializing in the development and provision of treatments for breast cancer gene (BRCA) mutations.

Major companies operating in the breast cancer gene (brca) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Genentech Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics.

North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (brca) mutations treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the breast cancer gene (brca) mutations treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the breast cancer gene (BRCA) mutations treatment market by increasing costs of imported targeted therapies, diagnostic kits, and biologic drugs, affecting overall treatment affordability. Targeted therapy and immunotherapy segments are most affected, particularly in regions such as North America and Europe that depend on global pharmaceutical supply chains. These cost pressures have influenced pricing and access to advanced therapies. However, tariffs have also encouraged local manufacturing, domestic R&D investment, and development of cost-effective treatment alternatives over the long term.

The breast cancer gene (brca) mutations treatment market research report is one of a series of new reports that provides breast cancer gene (brca) mutations treatment market statistics, including breast cancer gene (brca) mutations treatment industry global market size, regional shares, competitors with a breast cancer gene (brca) mutations treatment market share, detailed breast cancer gene (brca) mutations treatment market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer gene (brca) mutations treatment industry. This breast cancer gene (brca) mutations treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Breast cancer gene (BRCA) mutation treatment involves therapeutic approaches aimed at managing and reducing the risk of breast and ovarian cancers in individuals carrying pathogenic BRCA1 or BRCA2 mutations. It focuses on early identification of genetic mutations and the implementation of preventive and therapeutic strategies to improve patient outcomes.

The main types of breast cancer gene (BRCA) mutation treatments include targeted therapies, chemotherapy, hormonal therapy, and immunotherapy. Targeted therapies are medications developed to selectively interfere with specific molecules or signaling pathways essential for cancer cell growth, allowing for more precise treatment with reduced impact on healthy cells. These therapies are used across multiple indications, including breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer. They are administered through various routes of administration such as oral, intravenous, and subcutaneous, and are utilized by different end users, including hospitals, clinics, and cancer specialty centers.

The breast cancer gene (BRCA) mutations treatment market consists of revenues earned by entities by providing services such as genetic testing and counseling, targeted therapy administration, radiation therapy, surgical interventions (including mastectomy and oophorectomy), and post-treatment follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer gene (BRCA) mutations treatment market also includes sales of genetic breast cancer gene (BRCA) testing kits, homologous recombination deficiency (HRD) assays, imaging tools, and emerging preventive immunotherapy vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.